Press Releases


Sep 18, 2013

RAMAT GAN, Israel (September 18, 2013) – LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ smartphone-based medical device and diabetes management system, announces that Dario is the subject of a comprehensive profile in Diabetes Daily, a leading online support network for people with diabetes.  The article is available at:

“As we prepare for receipt of the CE mark for Dario and the subsequent product launch in targeted European geographies, we are delighted Dario is receiving increasing recognition among the diabetes community,” said Erez Raphael, LabStyle’s President and CEO.  “Dario is a fresh, modern and comprehensive system for insulin-dependent diabetics to manage their disease, and online sales and marketing activities are central to our commercial plan.”

About Diabetes Daily

Founded by Elizabeth Zabell Edelman and David Edelman, Diabetes Daily is a leading online support network that helps people affected by diabetes live a better life.  The online support network features one of the largest diabetes forums, as well as original recipes, meal plans, cookbooks, blogs, educational resources, online blood glucose tracking, health challenges and diabetes related news.  Diabetes Daily’s mission is to connect people with diabetes, facilitate education and promote advocacy.  Since its inception in 2005, the support network has grown to include 60,000 members and 3 million annual visitors.  In 2011 the network launched Diabetes Daily University to provide tools, information, courses and personal coaching from global leaders in diabetes education. Consumers can join the network at or register for Diabetes Daily University at

About LabStyle Innovations

LabStyle Innovations Corp. (OTCQB: DRIO) is developing and commercializing a patent-pending technology that seeks to bring rapid diagnostic capabilities to consumers in a distinctive and easy-to-use way through the use of smartphones such as iPhones, Androids and other mobile devices. LabStyle’s initial product is Dario™, an integrated medical device and software system addressing the market for diabetic self monitoring of blood glucose (SMBG), a market which is estimated to exceed $10 billion worldwide. Dario is a comprehensive, patent-pending system that combines an all-in-one medical device consisting of an integrated lancet (to obtain a blood sample), a device-specific disposable test strip cartridge and a smartphone-driven glucose reader adaptor, together with a smartphone app and cloud-based data services. LabStyle is pursuing patent applications in multiple jurisdictions covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information, please visit

Cautionary Note Regarding Forward-Looking Statements

This news release, the investor presentation referred to herein, and the statements of representatives and partners of LabStyle Innovations Corp. (the Company) related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Statements that are not statements of historical fact may be deemed to be forward-looking statements.  Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements.  Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release.  Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources.  Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission.  Readers are cautioned that actual results may differ significantly from those set forth in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 




Bruce Voss

LabStyle Innovations Corp.

Dr. Oren Fuerst,
Executive Chairman